Bronstein, Gewirtz & Grossman, LLC Is Investigating Cellectis S.A. (CLLS) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / September 17, 2026 /Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cellectis S.A. ("Cellectis" or "the Company") (NASDAQ:CLLS). Investors who purchased Cellectis securities are encouraged to obtain additional information and assist the investigation by visiting the firm 's site: bgandg.com/cases/cellectis-sa-clls-class_action_lawsuit.
Cellectis Investigation Details
On September 14, 2026, Cellectis announced it would prioritize in vivo gene editing therapies (HEAL-101 and HEAL-201) over CAR-T cell therapies. The Company concurrently announced it plans to discontinue the development of CAR-T cell therapies lasme-cel and eti-cel. In the accompanying conference call, the Company 's Chief Medical Officer, Adrian Kilcoyne stated "Cellectis is not able finance [Eti-cel and Lasme-cel] given the time lines that we have and the limited cash resources that we have." Following this news, Cellectis 's stock price dropped $1.27 per share, or 40.97%, to close at $1.83 on September 14, 2026.
What 's Next for Cellectis Investors?
If you are aware of any facts relating to this investigation or purchased Cellectis securities, you can assist this investigation by visiting the firm 's site: bgandg.com/cases/cellectis-sa-clls-class_action_lawsuit. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Cellectis Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys ' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Cellectis Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE:Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
